Autopsy report · NCT00807170

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

“Very slow recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 1 year 3 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Sanofi

Sponsor type

Industry

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

ZD6474 (Vandetanib); Whole Brain Radiotherapy (WBRT); ZD6474; ZD6474

Participants

5

Sites

3

Countries

Netherlands

Trials that died the same way

• In-vivo Wear Behaviour of AS Coated Versus Uncoated Columbus® Total Knee Prosthesis
  “Recruitment too slow” (96% match in meaning)
• Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens
  “recruitment slow” (95% match in meaning)
• Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis
  “Slow recruitment” (95% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.